ClinicalTrials.gg
RecruitingNCT04952480DARTSUpdated Nov 3, 2026

Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer

A Phase 2 interventional study of Dose-escalated adaptive radiotherapy and Chemotherapy in Small Cell Lung Cancer, sponsored by AHS Cancer Control Alberta. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by AHS Cancer Control Alberta · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.
Updated Nov 3, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 96 studies in Small Cell Lung Carcinoma with a site in Canada — 15 open to participants now, 31 under way, 14 of them phase 3. Small Cell Lung Carcinoma · Canada.

Planned enrollment
68th of 90
31 · median 132
Started
2022
with 3 others
Phase 2
21 of 96
2 open now
Primary completion
2028-03
later than 19 of 30 live
Registered
76th of 96
by date
Lead sponsor
7 of 96
AHS Cancer Control Alberta

Among the 96 studies in Small Cell Lung Carcinoma with a site in Canada, this one is the 68th largest by planned enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2022, is one of 21 in phase 2, reaches primary completion later than 19 of the 30 other live ones, and was the 76th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

15 of the 96 studies in Small Cell Lung Carcinoma with a site in Canada are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Small Cell Lung Carcinoma with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to find out what effects of using adaptive radiotherapy to deliver chest radiation has on the ability to control lung cancer and side effects.

Read the detailed description

This will be an open-label, single-arm, phase II study comparing dose escalated adaptive thoracic radiotherapy to historical control of standard of care single planned radiotherapy field for entire treatment course in patients with newly diagnosed limited stage small cell lung cancer eligible for concurrent chemoradiation with platinum doublet based chemotherapy, or extensive stage small cell lung cancer patients with radiation-targetable intra-thoracic disease and none or limited extra-thoracic disease that are eligible for up-front platinum doublet chemotherapy and are fit to receive concurrent radiotherapy.

The adaptive dose-escalated radiotherapy treatment plan will be delivered in three sequential phases with two scheduled replans during the treatment along with scaled dose limits for organs-at-risk. Up to 70 Gy in 35 fractions can be delivered to the disease without overdosing organs-at-risk, and treatment will last 5 - 7 weeks. Scheduled CT simulations for the replans will be at fraction 5 and fraction 10 to account for the expected rapidly shrinking tumour volumes. Participants will be followed for 24 months to investigate local failure rate, medium progression-free survival, overall survival, acute radiation toxicity, and late radiation toxicity. Follow-up after the study will be as per standard-of-care for secondary endpoints.

03

Conditions studied

  • Small Cell Lung Cancer

Keywords

  • Small cell lung cancer
  • (Dose-escalated) Adaptive radiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minimum 18 years of age
  • proven, newly diagnosed, untreated SCLC
  • Completed standard of care staging investigations including: CT chest/abdomen/pelvis, bone scan and/or or PET-CT scan, CT head or MRI brain, or chest X-ray
  • Eligible for platinum doublet chemotherapy
  • Eligible for thoracic radiotherapy, which can also include ipsilateral supraclavicular lymph node disease
  • Capable of providing written, prior to participation in the study. Patient's legally authorized representative (LAR) may sign on behalf of the patient.
  • Able and willing to comply with protocol rules and follow-up regimen
  • Performance status of 0-2
  • Pulmonary function tests showing FEV-1 >1.0L and DLCO > 50% predicted
  • Radiation-targetable intrathoracic disease

Exclusion criteria

Exclusion Criteria:

  • No intrathoracic disease seen to target with radiation
  • Thoracic disease is contiguous to extra-thoracic sites, beyond ipsilateral supraclavicular lymph nodes
  • Mixed histology disease
  • Active serious infection requiring therapy
  • that has not been symptomatically stable on dexamethasone
  • 4 or more sites of extrathoracic disease, even if 2 or more of these are present in the same organ system
  • Previous CNS or thoracic radiotherapy
  • Previous chemotherapy
  • Ineligibility for platinum doublet chemotherapy
  • of less than 3 months
  • Prior thoracic surgery
  • History of another primary other than cutaneous basal cell carcinoma unless disease-free for at least 5 years
  • Pregnant or breast-feeding
  • In LS-SCLC, patients that are not eligible for concurrent chemoradiotherapy
  • In ES-SCLC, patients that are not eligible for concurrent chemoradiotherapy under the experimental arm
  • CT contrast allergy or kidney disease with irreversibly low inadequate for IV contrast administration (for the purposes of high quality contrast enhanced CT chest and abdomen for follow-up imaging)
  • Lack of intrathoracic disease or intrathoracic disease spread not feasible to treat with adaptive radiotherapy
  • Participant in development and conduct of the research study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    Dose-escalated adaptive chemoradiotherapy

    Concurrent with standard of care platinum doublet based chemotherapy (cisplatin + etoposide), radiation treatment plan will be delivered in three sequential phases with two scheduled replans during the treatment along with scaled dose limits for organs-at-risk: Phase 1 dose prescription = 14 Gy in 7 fractions; Phase 2 dose prescription = 10 Gy in 5 fractions starting the day after the final (7th) fraction is delivered; Phase 3 dose prescription = either a) 70 Gy in 35 fractions, or if this cannot be safely reached without exceeding the dose limit of an organ-at-risk, b) the maximum safe prescribe-able dose tolerance specified in the protocol. Either 3D conformal radiotherapy or IMRT planning and delivery techniques will be employed, including contouring relevant thoracic organs-at-risk. All CT simulation scans will be without contrast.

    Radiation: Dose-escalated adaptive radiotherapy · Drug: Chemotherapy

Interventions

  • RadiationDose-escalated adaptive radiotherapy

    Adaptive planning of Radiation Therapy with two re-plans of the treatment field through course of therapy with the shrinking treatment fields according to tumor response to escalate dose, as allowed by dose to organs-at-risk.

  • DrugChemotherapy

    Concurrent standard of care platinum doublet based therapy

06

What researchers measure

Primary outcomes

  1. Local failure rate

    The time from diagnostic biopsy to documented progression of intrathoracic disease as assessed by CT or X-ray imaging.

    Time frame: The local failure rate will be assessed at the time point of 24 months.

Secondary outcomes

  1. Progression-free survival

    Time from diagnostic biopsy to first documented clinical or radiographic evidence of local progression or new metastatic disease.

    Time frame: Median time to PFS in study population. Expected to be within 24 months.

  2. Overall survival

    Time from diagnostic biopsy to death of the patient.

    Time frame: Median time to OS in study population. Expected to be within 24 months.

  3. Acute radiation toxicity

    Toxicity during and in the 3 months after radiotherapy as defined by CTCAE v.5 for esophagus, skin, lung, heart, and subcutaneous tissue.

    Time frame: Expected to be within 3 months.

  4. Late radiation toxicity

    Toxicity seen 3 months after radiotherapy as defined by CTCAE v.5 for esophagus, skin, lung, heart, and subcutaneous tissue.

    Time frame: Late toxicity will be assessed up to 24 months post-treatment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Mar 2028, 69 months after the start.

Of 150 non-industry phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's planned 69 months is above that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Nov 2025 → Mar 2028 and completion Nov 2025 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2021
First posted
Jul 7, 2021
StartActual
Jun 13, 2022
Primary completionEst.
Mar 2028was Nov 2025
CompletionEst.
Mar 2028was Nov 2025
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 1, 2025→Mar 2028
Nov 3, 2026
Study completion
Nov 1, 2025→Mar 2028
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion Nov 1, 2025→Mar 2028
    Study completion Nov 1, 2025→Mar 2028
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04952480
Responsible party
Sponsor
First posted
Jul 7, 2021
Start date
Jun 13, 2022
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Yee Don, MD
Contact
don.yee@ahs.ca
780-432-8783
Yee Don, MD
principal investigator · Cross Cancer Institute, Alberta Health Services

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion